FIELD: biotechnology.
SUBSTANCE: T-cell receptor (hereinafter – TCL) is proposed that binds to SLLMWITQC peptide restricted by HLA-A*02, originating from cancer antigen NY-ESO-1. Fused protein TCR/anti-CD3 is also proposed, containing the specified TCR and an antibody against CD3. In addition, the invention relates to nucleic acid and an expression vector for the production of TCR or fused protein TCR/anti-CD3, to cells expressing TCR or fused protein.
EFFECT: fused proteins and cells, according to the present invention, are suitable for use as new immune-therapeutic reagents for the treatment of malignant disease.
44 cl, 12 dwg, 12 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
